Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2023

Aug 14, 2023

SELL
$2.49 - $20.59 $596,327 - $4.93 Million
-239,489 Reduced 73.95%
84,370 $227,000
Q1 2023

May 15, 2023

BUY
$15.95 - $25.18 $5.17 Million - $8.15 Million
323,859 New
323,859 $6.04 Million
Q3 2022

Nov 14, 2022

SELL
$11.4 - $14.6 $2.43 Million - $3.11 Million
-213,217 Reduced 57.07%
160,401 $2.09 Million
Q2 2022

Aug 15, 2022

BUY
$7.94 - $12.96 $67,100 - $109,524
8,451 Added 2.31%
373,618 $3.95 Million
Q1 2022

May 16, 2022

SELL
$12.02 - $16.79 $227,947 - $318,405
-18,964 Reduced 4.94%
365,167 $4.39 Million
Q4 2021

Feb 14, 2022

SELL
$9.93 - $15.39 $4.35 Million - $6.74 Million
-438,200 Reduced 53.29%
384,131 $5.42 Million
Q3 2021

Nov 15, 2021

BUY
$10.18 - $26.64 $5.8 Million - $15.2 Million
569,939 Added 225.82%
822,331 $8.4 Million
Q2 2021

Aug 16, 2021

BUY
$18.57 - $35.68 $4.69 Million - $9.01 Million
252,392 New
252,392 $6.72 Million
Q3 2020

Nov 16, 2020

SELL
$40.47 - $45.5 $1.25 Million - $1.4 Million
-30,819 Closed
0 $0
Q2 2020

Aug 14, 2020

BUY
$32.57 - $42.83 $1 Million - $1.32 Million
30,819 New
30,819 $1.25 Million
Q1 2020

May 15, 2020

SELL
$23.3 - $45.96 $323,753 - $638,614
-13,895 Closed
0 $0
Q4 2019

Feb 14, 2020

BUY
$34.58 - $48.06 $480,489 - $667,793
13,895 New
13,895 $596,000
Q1 2018

May 15, 2018

SELL
$45.35 - $61.65 $660,250 - $897,562
-14,559 Closed
0 $0
Q4 2017

Feb 14, 2018

SELL
$41.95 - $60.1 $2.22 Million - $3.17 Million
-52,825 Reduced 78.39%
14,559 $690,000
Q3 2017

Nov 14, 2017

BUY
$33.4 - $53.9 $2.25 Million - $3.63 Million
67,384
67,384 $3.63 Million

Others Institutions Holding FGEN

About FIBROGEN INC


  • Ticker FGEN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 93,741,200
  • Market Cap $32.8M
  • Description
  • FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases, which has completed Phase III clinical development for the treatment of anemia in chronic k...
More about FGEN
Track This Portfolio

Track Voloridge Investment Management, LLC Portfolio

Follow Voloridge Investment Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Voloridge Investment Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Voloridge Investment Management, LLC with notifications on news.